Zacks Investment Research upgraded shares of REGULUS THERAP (RGLS) from NEUTRAL to OUTPERFORM on January 05, 2015, with a target price of $18.70.
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on REGULUS THERAP (RGLS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment